Oncology (all articles)
RCT: Short-term radiotherapy plus chemotherapy vs. long-term chemoradiotherapy in locally advanced rectal cancer.
18 Mar, 2022 | 07:39h | UTC
Summary: German evidence-based guidelines on focal therapy in localized prostate cancer.
17 Mar, 2022 | 08:47h | UTC
Review: Mechanistic and clinical overview of cardiovascular toxicity with BRAF and MEK inhibitors.
17 Mar, 2022 | 08:34h | UTC
Commentary on Twitter
New #JACCCardioOnc issue is out!
BRAF/MEK inhibitors are associated w/ adverse CV effects including HTN, LV dysfunction, #VTE, atrial arrhythmias, & QT prolongation. Learn more in this state-of-the-art review: https://t.co/2r9L90DTmL#CardioOnc #CardioTwitter #Hypertension pic.twitter.com/Dz8i0sfBTU
— JACC Journals (@JACCJournals) March 15, 2022
Trends in HPV–associated cancers, demographic characteristics, and vaccinations in the US, 2001-2017.
17 Mar, 2022 | 08:16h | UTCAuthor Interview: Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations
Related:
Three-year follow-up of 2-dose versus 3-dose HPV vaccine
CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination
Meta-Analysis: Population-level Impact of HPV Vaccination Programs
Cohort Study: Incident cardiovascular disease among adults with cancer.
17 Mar, 2022 | 08:10h | UTCCommentaries:
New Cancer Diagnosis May Up Risk for CV Death, Morbidity – HealthDay
What is the Incidence of CVD Among Adults With Cancer? – American College of Cardiology
Commentary on Twitter
A new cancer diagnosis may be independently associated with a "significantly higher risk" for cardiovascular death, #stroke, #HeartFailure, and pulmonary embolism, especially in the first year, according to a study in #JACCCardioOnc. https://t.co/XboZ2Ivsdl @JACCJournals
— American College of Cardiology (@ACCinTouch) March 16, 2022
Cohort Study: adjuvant vs. early salvage radiation therapy after radical prostatectomy for pN1 prostate cancer.
17 Mar, 2022 | 08:09h | UTC
RCT: Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma.
17 Mar, 2022 | 08:07h | UTC
Commentary on Twitter
Phase III JUPITER-03 trial testing addition of the anti-PD-1 mAb toripalimab to first-line chemotherapy for advanced-stage ESCC, mPFS was 5.7 vs 5.5 months, although 1-year PFS was 27.8% vs 6.1% (HR 0.58) and mOS was 17 vs 11 months (HR 0.58): https://t.co/jNSVzNiAzR #esocsm
— NatureRevClinOncol (@NatRevClinOncol) March 10, 2022
Systematic Review: Perioperative enhanced recovery programs for women with gynecological cancers.
16 Mar, 2022 | 10:05h | UTCPerioperative enhanced recovery programmes for women with gynaecological cancers – Cochrane Library
See also: Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines (some guidelines are free)
RCT: In women undergoing cytoreductive surgery for ovarian cancer, the addition of hyperthermic intraperitoneal chemotherapy did not improve progression-free and overall survival.
16 Mar, 2022 | 09:41h | UTCRelated:
M-A: Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer.
RCT: Cytoreductive surgery for relapsed ovarian cancer.
Multicenter comparative accuracy trial: Dynamic contrast-enhanced CT vs. positron emission tomography CT to characterize solitary pulmonary nodules.
16 Mar, 2022 | 08:51h | UTCDownload: Full Report
A contemporary systematic review on liver transplantation for unresectable liver metastases of colorectal cancer.
16 Mar, 2022 | 08:37h | UTC
M-A: Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer.
16 Mar, 2022 | 08:30h | UTC
RCT: Observation vs. screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases.
16 Mar, 2022 | 08:26h | UTC
Commentary on Twitter
In @LancetOncology : Brilliant question answered by this RCT👉Any role of screening for malignant spinal cord compression & pre-emptive Rx in asymptomatic mCRPC #prostatecancer ? Answer is "NO". Congrats to @DearnaleyProf & team Free access: https://t.co/8r4yJOYCLA @OncoAlert pic.twitter.com/8oLIwKKOx1
— Neeraj Agarwal, MD, FASCO (@neerajaiims) March 12, 2022
NCCN Guideline: T-Cell Lymphomas.
15 Mar, 2022 | 08:41h | UTC
Systematic Review: De-implementing low-value care in cancer care delivery.
15 Mar, 2022 | 08:22h | UTCDe-implementing low-value care in cancer care delivery: a systematic review – Implementation Science
M-A: Reassessment of the efficacy of carboplatin for metastatic urothelial carcinoma in the era of immunotherapy.
15 Mar, 2022 | 08:05h | UTC
Systematic review and non-inferiority meta-analysis of randomized phase II/III trials on S-1-based therapy vs. 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer.
15 Mar, 2022 | 08:06h | UTC
Systematic Review: Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
14 Mar, 2022 | 01:17h | UTCPoly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer – Cochrane Library
RCT: Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer.
14 Mar, 2022 | 00:41h | UTC
Mutational signatures and processes in hepatobiliary cancers.
14 Mar, 2022 | 00:43h | UTCMutational signatures and processes in hepatobiliary cancers – Nature Reviews Gastroenterology & Hepatology (if the link is paywalled, try this one)
Commentary on Twitter
Appeared online this week in @NatRevGastroHep 🧵
"Mutational signatures and processes in hepatobiliary cancers" a #Review article
Read here 👉🏾https://t.co/fUcaZ81BSA
Attached Figure: a clinicopathological and molecular overview of hepatobiliary cancers pic.twitter.com/d6MVAFu0J1— Nature Reviews Gastroenterology & Hepatology (@NatRevGastroHep) March 11, 2022
Management and care of patients with invasive cervical cancer: ASCO resource-stratified guideline rapid recommendation update.
14 Mar, 2022 | 00:40h | UTCNews Release: ASCO Guideline Recommends Addition of Monoclonal Antibody to Invasive Cervical Cancer Management – ASCO Daily News
RCT: Overall survival with Ribociclib plus Letrozole in advanced breast cancer.
11 Mar, 2022 | 09:47h | UTCOverall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Adding Ribociclib to Letrozole Prolongs Survival in Advanced Breast Cancer – HealthDay
Review: Current surgical indications for non-small-cell lung cancer.
11 Mar, 2022 | 08:39h | UTCCurrent Surgical Indications for Non-Small-Cell Lung Cancer – Cancers
RCT: In patients with low-risk thyroid cancer, thyroidectomy without ablation radioiodine was noninferior to thyroidectomy with ablation radioiodine at 3 years.
10 Mar, 2022 | 10:59h | UTCThyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: New research casts doubt on a cornerstone of thyroid cancer treatment – STAT
Commentary on Twitter
In RCT involving patients with low-risk differentiated thyroid cancer undergoing thyroidectomy, a follow-up strategy that did not involve the use of radioiodine was noninferior to the use of radioiodine in the response to treatment at 3 years. https://t.co/RaJL3tdE4T pic.twitter.com/8nIPw50nkg
— NEJM (@NEJM) March 9, 2022
GEC ESTRO ACROP consensus recommendations for contact brachytherapy for rectal cancer.
10 Mar, 2022 | 10:35h | UTC